1010085-13-8 | MK-5108

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$36.00	$25.00
5mg	98%	in stock	$79.00	$55.00
10mg	98%	in stock	$144.00	$101.00
25mg	98%	in stock	$246.00	$172.00
50mg	98%	in stock	$486.00	$341.00
100mg	98%	in stock	$809.00	$566.00

Description

• Catalog Number: AE11285
• Chemical Name: MK-5108
• CAS Number: 1010085-13-8
• Molecular Formula: C22H21ClFN3O3S
• Molecular Weight: 461.9368
• MDL Number: MFCD22124479
• SMILES: OC(=O)C1(CCC(CC1)Oc1cccc(c1F)Cl)Cc1cccc(n1)Nc1nccs1

Computed Properties

• Complexity: 611
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 31
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 7
• XLogP3: 5.4

Upstream Synthesis Route

MK-5108, a selective Aurora A kinase inhibitor, plays a crucial role in chemical synthesis by serving as a potent tool for the development of various pharmaceutical compounds. This compound boasts a high degree of selectivity towards the Aurora A kinase enzyme, making it a valuable asset in the field of medicinal chemistry. Researchers and chemists often utilize MK-5108 in the synthesis of novel drug candidates, particularly those targeted at cancer treatment.In chemical synthesis, MK-5108 can be employed to create unique molecular structures with specific pharmacological properties. By inhibiting Aurora A kinase, this compound can modulate diverse signaling pathways involved in cell division and proliferation. This mechanism of action is particularly relevant in cancer research, where uncontrolled cell growth is a hallmark of the disease. Through precise manipulation of Aurora A kinase activity, chemists can design innovative drugs that target cancer cells with high specificity, minimizing adverse effects on healthy tissues.Furthermore, the application of MK-5108 in chemical synthesis extends beyond oncology. Its ability to modulate cellular processes opens up possibilities for developing therapies for various other diseases, including neurodegenerative disorders and autoimmune conditions. By harnessing the power of selective Aurora A kinase inhibition, chemists can explore new avenues in drug discovery and design, paving the way for innovative treatments with improved efficacy and safety profiles.

Literature

• Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.

  Journal of molecular biology 20170217

• A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120615

• Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.

  Cancer research 20110601

• Aurora kinase inhibitors as anti-cancer therapy.

  Anti-cancer drugs 20100401

• MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.

  Molecular cancer therapeutics 20100101